Intercell, Novartis vaccine goes into PhII; Pfizer's Prevnar effective in adolescents;

> Intercell has started a pivotal Phase II/III efficacy study of its Pseudomonas aeruginosa vaccine candidate. The move comes after a Phase II trial showed the vaccine reduced death rates; the vaccine is part of a strategic alliance with Novartis ($NVS). Intercell release

> PX'Therapeutics is launching a Phase I clinical trial of an HIV prophylactic vaccine as part of the EU collaborative project EuroNeut-41. PX'Therapeutics release

> Patient recruitment has started for an early clinical trial for PD01, an experimental Parkinson's disease vaccine from AFFiRiS. Article

> Pfizer's ($PFE) Prevnar, currently approved for use in infants and young children, has shown efficacy in children and young people up to the age of 17. Pfizer release

> Taiwan's Adimmune is planning clinical trials for its domestic H5N1 vaccine. Article

> Flu vaccines are safe for most children with egg allergies. News

> India welcomes the Gennova Vaccine Formulation Center, a $7.9 million facility dedicated to manufacturing vaccines. Story

> Ghana has approval from the WHO to launch four meningitis vaccines. Item

And Finally… The Infectious Disease Research Institute has received a $1 million grant to develop a leprosy diagnostic and vaccine as part of an effort to eliminate the disease. IDRI release

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.